# Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

> **NCT06669754** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pharvaris Netherlands B.V.** · enrollment: 81 (estimated)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** Deucrictibant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06669754
- **Lead sponsor:** Pharvaris Netherlands B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669754, "Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06669754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*